AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3067374 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 52
Study 31491535 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval of online Problem‐Solving Therapy (PST) sessions
Number of subjects: 95
Study 31491535 — intervention group
Group type: COMPARATOR
Intervention: Rehearsal of online Problem‐Solving Therapy (PST) sessions
Number of subjects: 95
Study 29914814 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (CAC)
Number of subjects: 222
Study 29914814 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 222
Study 29914814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CAC and RFA
Number of subjects: 222
Study 26949691 — intervention group
Group type: EXPERIMENTAL
Intervention: SB predilation before stenting the main branch (n = 30)
Number of subjects: 60
Study 26949691 — intervention group
Group type: COMPARATOR
Intervention: No predilation (Control group, n = 30)
Number of subjects: 60
Study 26949691 — intervention group
Group type: EXPERIMENTAL
Intervention: SB predilation
Number of subjects: 60
Study 26116425 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine 900 mg/day
Number of subjects: 24
Study 26116425 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine 600 mg/day
Number of subjects: 24
Study 26116425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23860343 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg/kg infusion
Number of subjects: 9
Study 21663622 — intervention group
Group type: COMPARATOR
Intervention: Standard macronutrient content (maximum protein 2.8 g/kg/day; lipid 2.8 g/kg/day, dextrose 10%)
Number of subjects: 150
Study 21663622 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher macronutrient content (maximum protein 3.8 g/kg/day; lipid 3.8 g/kg/day, dextrose 12%)
Number of subjects: 150
Study 21663622 — intervention group
Group type: COMPARATOR
Intervention: Standard macronutrient content
Number of subjects: 150
Study 21663622 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher macronutrient content
Number of subjects: 150
Study 18499010 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual phacoemulsification
Number of subjects: 180
Study 18499010 — intervention group
Group type: COMPARATOR
Intervention: Standard coaxial phacoemulsification
Number of subjects: 180
Study 18499010 — intervention group
Group type: COMPARATOR
Intervention: Microcoaxial phacoemulsification
Number of subjects: 180
Study 16598443 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (12.5 mg orally before PCI, uptitrated to 50 mg daily)
Number of subjects: 100
Study 16598443 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (50 mg orally before PCI, uptitrated to 150 mg daily)
Number of subjects: 100
Study 14604447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine CR (100-300 mg/d)
Number of subjects: 112
Study 14604447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 10893476 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 45
Study 9430864 — intervention group
Group type: EXPERIMENTAL
Intervention: HighBic. (40 mmol/l) bicarbonate dialysate
Number of subjects: 46
Study 9430864 — intervention group
Group type: COMPARATOR
Intervention: LowBic. (30 mmol/l) bicarbonate dialysate
Number of subjects: 46
Study 8505940 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 178
Study 8505940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 3799495 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumpkin-seed supplementation 60 mg X kg body wt-1 X day-1
Number of subjects: 20
Study 3799495 — intervention group
Group type: COMPARATOR
Intervention: Orthophosphate supplementation 60 mg X kg body wt-1 X day-1
Number of subjects: 20
Study 3799495 — intervention group
Group type: COMPARATOR
Intervention: Oxalate supplementation 5 mg X kg-1 body wt X day-1
Number of subjects: 20
Study 3799495 — intervention group
Group type: COMPARATOR
Intervention: Control (before treatment)
Number of subjects: 20
Study 3799495 — intervention group
Group type: COMPARATOR
Intervention: Posttreatment
Number of subjects: 20
Study 29107430 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPS (eAlert! System)
Number of subjects: 197
Study 29107430 — intervention group
Group type: COMPARATOR
Intervention: Control (telephone follow-up only)
Number of subjects: 197
Study 27483038 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D supplementation (1,000 mg of elemental calcium as calcium carbonate with 400 IU of vitamin D3 daily)
Number of subjects: 36282
Study 27483038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 27483038 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium + Vitamin D supplementation
Number of subjects: 36282
Study 23644937 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral laser microsurgery (TLM)
Number of subjects: 24
Study 23644937 — intervention group
Group type: COMPARATOR
Intervention: Lip-split mandibulotomy (LSM)
Number of subjects: 24
Study 22990161 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent (n=8)
Number of subjects: 14
Study 22990161 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=6)
Number of subjects: 14
Study 20525445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonoelastography
Number of subjects: 30
Study 20525445 — intervention group
Group type: COMPARATOR
Intervention: B-mode ultrasound
Number of subjects: 30
Study 18165640 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson comorbidity index score (CCIS) 1
Number of subjects: 1255
Study 18165640 — intervention group
Group type: EXPERIMENTAL
Intervention: CCIS equal to or greater than 1
Number of subjects: 1255
Study 18165640 — intervention group
Group type: COMPARATOR
Intervention: Age greater than 65 years
Number of subjects: 1255
Study 15711271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (KT) plus hydrocortisone (H) plus alendronate (AL) (1,200 mg daily KT, 30 mg daily H, 40 mg daily AL)
Number of subjects: 72
Study 15711271 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (KT) plus hydrocortisone (H) (1,200 mg daily KT, 30 mg daily H)
Number of subjects: 72
Study 12825799 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis, no transport (Group A)
Number of subjects: 300
Study 12825799 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis during transport to an angioplasty centre (Group B)
Number of subjects: 300
Study 12825799 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport for primary angioplasty (Group C)
Number of subjects: 300
Study 12825799 — intervention group
Group type: COMPARATOR
Intervention: Control (Thrombolysis at nearest hospital)
Number of subjects: 300
Study 12825799 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 300
Study 12825799 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis during transport vs. transport for primary angioplasty alone
Number of subjects: 300
Study 11860783 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential hypertensive patients
Number of subjects: 297
Study 11860783 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 297
Study 11860783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 297
Study 8843295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (300 mg daily for 14 days)
Number of subjects: 12
Study 8843295 — intervention group
Group type: COMPARATOR
Intervention: Rifabutin (300 mg daily for 14 days)
Number of subjects: 12
Study 1364608 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicic enterosorbent 'Polysorba'
Number of subjects: 107
Study 3881051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0 mg of oral physostigmine
Number of subjects: 12
Study 3881051 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of oral physostigmine
Number of subjects: 12
Study 3881051 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg of oral physostigmine
Number of subjects: 12
Study 3881051 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg of oral physostigmine
Number of subjects: 12
Study 3881051 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg of oral physostigmine
Number of subjects: 12
Study 3881051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3881051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose associated with least severe symptoms
Number of subjects: 12
Study 29907435 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Subfascial approach
Number of subjects: 24
Study 29907435 — intervention group
Group type: COMPARATOR
Intervention: Subfascial approach
Number of subjects: 24
Study 26086180 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration (<6 hours/night)
Number of subjects: 7444
Study 26086180 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleep duration (>8 hours/night)
Number of subjects: 7444
Study 26086180 — intervention group
Group type: COMPARATOR
Intervention: Normal sleep duration (7 hours/night)
Number of subjects: 7444
Study 24660159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate (15 mg/kg)
Number of subjects: 70
Study 24660159 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (control)
Number of subjects: 70
Study 23522247 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine treatment (n=164)
Number of subjects: 256
Study 23522247 — intervention group
Group type: COMPARATOR
Intervention: control group (n=92)
Number of subjects: 256
Study 20530649 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric endurance training
Number of subjects: 14
Study 20530649 — intervention group
Group type: COMPARATOR
Intervention: Concentric training
Number of subjects: 14
Study 18671947 — intervention group
Group type: EXPERIMENTAL
Intervention: A. senticosus supplementation
Number of subjects: 40
Study 18671947 — intervention group
Group type: COMPARATOR
Intervention: Control group (calcium)
Number of subjects: 40
Study 18671947 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (calcium plus A. senticosus)
Number of subjects: 40
Study 15986343 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice a day for 30 months
Number of subjects: 431
Study 15986343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study 15986343 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 431
Study 12566640 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose rinse, 5 times daily
Number of subjects: 16
Study 12566640 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sucrose rinse, 10 times daily
Number of subjects: 16
Study 12566640 — intervention group
Group type: COMPARATOR
Intervention: Control (no mouth rinses)
Number of subjects: 16
Study 12566640 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% sucrose rinse, 5 times daily
Number of subjects: 16
Study 10336571 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg tablet (fasted)
Number of subjects: 12
Study 10336571 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg tablet (fed)
Number of subjects: 12
Study 10336571 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg intravenous (i.v.) infusion over 40 min (fasted)
Number of subjects: 12
Study 7573709 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyspecific snake antivenom
Number of subjects: 63
Study 7573709 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 63
Study 2016622 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (XRT) and vincristine-dactinomycin (VA) or VA plus cyclophosphamide (VAC) +/- doxorubicin
Number of subjects: 56
Study 2016622 — intervention group
Group type: COMPARATOR
Intervention: VAC +/- XRT (IRS-I)
Number of subjects: 56
Study 2016622 — intervention group
Group type: COMPARATOR
Intervention: VAC +/- XRT (IRS-II)
Number of subjects: 56
Study 2016622 — intervention group
Group type: COMPARATOR
Intervention: Other sites (comparison group)
Number of subjects: 56
Study 2016622 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with embryonal rhabdomyosarcoma (RMS)
Number of subjects: 56
Study 6456557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization and manipulation
Number of subjects: 188
Study 6456557 — intervention group
Group type: COMPARATOR
Intervention: Placebo physiotherapy
Number of subjects: 188
Study 31387822 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up (TFU) and 24/7 hotline
Number of subjects: 288
Study 31387822 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 288
Study 31510998 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% permethrin
Number of subjects: 77
Study 31510998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% parasidose (d-phenothrin)
Number of subjects: 77
Study 31510998 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% dimeticone
Number of subjects: 77
Study 27585055 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 52
Study 27585055 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AE)
Number of subjects: 52
Study 27585055 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 52
Study 26216386 — intervention group
Group type: EXPERIMENTAL
Intervention: SP3 (S‐1 80 mg/m2/day on days 1‐14 and cisplatin 60 mg/m2 on day 1)
Number of subjects: 625
Study 26216386 — intervention group
Group type: COMPARATOR
Intervention: SP5 (S‐1 80‐120 mg/day on days 1‐21 and cisplatin 60 mg/m2 on day 1 or 8)
Number of subjects: 625
Study 26216386 — intervention group
Group type: EXPERIMENTAL
Intervention: SP3
Number of subjects: 625
Study 26216386 — intervention group
Group type: COMPARATOR
Intervention: SP5
Number of subjects: 625
Study 24328357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg/day
Number of subjects: 12
Study 24328357 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 12
Study 22327347 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis BB‐12 (BB‐12)
Number of subjects: 106
Study 22327347 — intervention group
Group type: COMPARATOR
Intervention: Xylitol (X group)
Number of subjects: 106
Study 22327347 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol (S group)
Number of subjects: 106
Study 19405802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: Local infiltration of port sites with 10 mL of ropivacaine
Number of subjects: 30
Study 19405802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: Infiltration of port sites with 10 mL of ropivacaine and intraperitoneal instillation of 10 mL of ropivacaine
Number of subjects: 30
Study 19405802 — intervention group
Group type: COMPARATOR
Intervention: Group C: No analgesic treatment
Number of subjects: 30
Study 17290056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (DRZ)
Number of subjects: 478
Study 17290056 — intervention group
Group type: COMPARATOR
Intervention: No Dexrazoxane (non-DRZ)
Number of subjects: 478
Study 15457308 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management (SM) of warfarin using a point-of-care device (Pro Time Microcogulation System)
Number of subjects: 140
Study 15457308 — intervention group
Group type: COMPARATOR
Intervention: Physician-management (PM) of warfarin
Number of subjects: 140
Study 11206237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine, 120 mg
Number of subjects: 12
Study 11206237 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast, 10 mg
Number of subjects: 12
Study 11206237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine and montelukast administered concurrently
Number of subjects: 12
Study 11206237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11206237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 12
Study 11206237 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 12
Study 9542492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine plus prazosin (200 mg single dose)
Number of subjects: 12
Study 9542492 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus prazosin
Number of subjects: 12
Study 9542492 — intervention group
Group type: EXPERIMENTAL
Intervention: Open evaluation of ibopamine plus prazosin
Number of subjects: 12
Study 8184117 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based limited volume irradiation with face masks for field alignment
Number of subjects: 0
Study 8184117 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated CT examinations after simulation
Number of subjects: 0
Study 2475690 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 24
Study 2475690 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional formulation of verapamil
Number of subjects: 24
Study 2475690 — intervention group
Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 24
Study 336110 — intervention group
Group type: EXPERIMENTAL
Intervention: d.1 5 hydroxy-tryptophan (600 mg a day)
Number of subjects: 11
Study 336110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 30803543 — intervention group
Group type: EXPERIMENTAL
Intervention: XP-endo Shaper (XP)
Number of subjects: 30
Study 30803543 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc Blue (RB)
Number of subjects: 30
Study 30803543 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Universal (PTU)
Number of subjects: 30
Study 28327896 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional bleomycin (90,000 units infusion over 72 hours)
Number of subjects: 212
Study 28327896 — intervention group
Group type: COMPARATOR
Intervention: Conventional BEP with weekly bleomycin (30,000 units/week i.v. bolus)
Number of subjects: 212
Study 28327896 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional bleomycin
Number of subjects: 212
Study 28327896 — intervention group
Group type: COMPARATOR
Intervention: Conventional BEP with weekly bleomycin
Number of subjects: 212
Study 25296647 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care and a sacral prophylactic dressing
Number of subjects: 80
Study 25296647 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 80
Study 23236022 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg/d cyanocobalamin for 8 weeks
Number of subjects: 100
Study 23236022 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg/d cyanocobalamin for 8 weeks
Number of subjects: 100
Study 23236022 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg/d cyanocobalamin for 8 weeks
Number of subjects: 100
Study 23236022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20957423 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced arm (nurse-delivered adherence intervention with electronic reminder device and counseling)
Number of subjects: 70
Study 20957423 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard intervention with educational session, pillbox, and referral to peer support group)
Number of subjects: 70
Study 19345767 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral medicine intervention
Number of subjects: 67
Study 19345767 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 67
Study 17718366 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving finger with a raised line present
Number of subjects: 0
Study 17718366 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving finger with no raised line present
Number of subjects: 0
Study 15338504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 200 mg qd
Number of subjects: 1042
Study 15338504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 400 mg qd
Number of subjects: 1042
Study 15338504 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg tid
Number of subjects: 1042
Study 15338504 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg qd
Number of subjects: 1042
Study 11575411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 24
Study 11575411 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 24
Study 9645980 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid balloon angioplasty
Number of subjects: 29
Study 8294693 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 5025
Study 8294693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5025
Study 2738720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG) 750 mg/kg
Number of subjects: 20
Study 2738720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29271278 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU of oral vitamin D3 once weekly)
Number of subjects: 44
Study 29271278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27593544 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Ecologic Barrier, Winclove, Amsterdam, The Netherlands) daily for 6 months
Number of subjects: 80
Study 27593544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 24753491 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 12 months
Number of subjects: 507
Study 24753491 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 507
Study 23425142 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment and chlorhexidine body wash (treated carriers)
Number of subjects: 738
Study 23425142 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated carriers)
Number of subjects: 738
Study 23425142 — intervention group
Group type: COMPARATOR
Intervention: No treatment (non-carriers)
Number of subjects: 738
Study 20015040 — intervention group
Group type: EXPERIMENTAL
Intervention: 11β-HSD1 selective inhibitors (e.g., DIO-902, INCB13739)
Number of subjects: 0
Study 20015040 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel chemicals that inhibit 11β-HSD1 reductase and increase oxidase activity
Number of subjects: 0
Study 19100003 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus Hydrochlorothiazide 12.5 mg (TH)
Number of subjects: 345